<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05029063</url>
  </required_header>
  <id_info>
    <org_study_id>TRIMLine CTO3698</org_study_id>
    <nct_id>NCT05029063</nct_id>
  </id_info>
  <brief_title>Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters</brief_title>
  <acronym>TRIM-Line</acronym>
  <official_title>Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the full trial is to determine the efficacy and safety of prophylactic dose&#xD;
      rivaroxaban to prevent VTE among cancer patients with CVC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TRIM-Line is a double blind randomized controlled trial comparing rivaroxaban 10mg po daily&#xD;
      vs placebo in patients with active cancer and indwelling CVC. This will involve 9 centers&#xD;
      across Canada.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind Randomized Control Trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Major VTE prevention</measure>
    <time_frame>90 days (± 3 days) of randomization</time_frame>
    <description>Number of Major VTE's in patient population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Episodes of Major Bleeding</measure>
    <time_frame>90 days (± 3 days) of randomization</time_frame>
    <description>Number of participants who had a major bleed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Clinically Relevant Non-Major Bleeding (CRNMB)</measure>
    <time_frame>90 days (± 3 days) of randomization</time_frame>
    <description>As defined by ISTH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who had a fatal VTE</measure>
    <time_frame>90 days (± 3 days) of randomization</time_frame>
    <description>Fatal VTE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who benefitted from using the experimental intervention</measure>
    <time_frame>90 days (± 3 days) of randomization</time_frame>
    <description>Composite of major VTE and major bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PE</measure>
    <time_frame>90 days (± 3 days) of randomization</time_frame>
    <description>Incidental and Symptomatic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proximal CVC VTE</measure>
    <time_frame>90 days (± 3 days) of randomization</time_frame>
    <description>Incidental and symptomatic proximal (axillary vein or more proximal) upper extremity CVC-related DVT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal CVC VTE</measure>
    <time_frame>90 days (± 3 days) of randomization</time_frame>
    <description>Incidental and symptomatic distal (brachial vein) or proximal (axillary vein or more proximal) upper extremity CVC-related DVT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proximal Lower extremity DVT</measure>
    <time_frame>90 days (± 3 days) of randomization</time_frame>
    <description>Incidental and symptomatic proximal (popliteal vein or more proximal) lower extremity DVT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal Lower extremity DVT</measure>
    <time_frame>90 days (± 3 days) of randomization</time_frame>
    <description>Incidental and symptomatic distal or proximal (popliteal vein or more proximal) lower extremity DVT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Unusual site thrombosis including: splanchnic vein (portal, splenic, superior mesenteric, inferior mesenteric, hepatic) cerebral vein, renal or gonadal vein thromboses</measure>
    <time_frame>90 days (± 3 days) of randomization</time_frame>
    <description>Unusual site thrombosis including: splanchnic vein (portal, splenic, superior mesenteric, inferior mesenteric, hepatic) cerebral vein, renal or gonadal vein thromboses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Superficial upper or lower extremity vein thrombosis</measure>
    <time_frame>90 days (± 3 days) of randomization</time_frame>
    <description>Superficial upper or lower extremity vein thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with an arterial thromboembolic event including: MI, stroke, peripheral arterial disease</measure>
    <time_frame>90 days (± 3 days) of randomization</time_frame>
    <description>Arterial thromboembolic event defined as the adjudicated presence of a final clinical diagnosis of thrombosis/thromboembolism diagnostically confirmed, including myocardial infarction, stroke, peripheral arterial disease and involving the following arterial vascular beds: carotid, upper or lower extremity, gastrointestinal tract, liver, spleen, or kidney</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CVC Life-span</measure>
    <time_frame>90 days (± 3 days) of randomization</time_frame>
    <description>Life span of inserted CVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with CVC occlusion occurring after the start of therapy, defined as an obstruction of the CVC lumen that prevents or limits the ability to flush, withdraw blood and/or administer solutions or medications.</measure>
    <time_frame>90 days (± 3 days) of randomization</time_frame>
    <description>CVC occlusion occurring after the start of therapy, defined as an obstruction of the CVC lumen that prevents or limits the ability to flush, withdraw blood and/or administer solutions or medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with CVC-related blood stream infection defined as the presence of bacteremia originating from the CVC according to the definition from the Centers for Disease Control and Prevention</measure>
    <time_frame>90 days (± 3 days) of randomization</time_frame>
    <description>CVC-related blood stream infection defined as the presence of bacteremia originating from the CVC according to the definition from the Centers for Disease Control and Prevention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who passed away during the trial</measure>
    <time_frame>90 days (± 3 days) of randomization</time_frame>
    <description>Overall mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L Health-related quality of life</measure>
    <time_frame>90 days (± 3 days) of randomization</time_frame>
    <description>Health-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICER</measure>
    <time_frame>1 Year</time_frame>
    <description>Incremental cost-effectiveness ratio (ICER) at one year</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1828</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban 10mg OD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical Placebo 10mg OD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 10 MG</intervention_name>
    <description>Identical comparator drug</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 years of age or older with a new or existing diagnosis of cancer and a CVC&#xD;
             inserted in the last 72 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. CVC in place for &gt;72 hours&#xD;
&#xD;
          2. Patient requires anticoagulation for other indication&#xD;
&#xD;
          3. Concomitant use of dual antiplatelet therapy&#xD;
&#xD;
          4. Major bleeding event in the last 4 weeks&#xD;
&#xD;
          5. Patients receiving concomitant systemic treatment with strong inhibitors of both CYP&#xD;
             3A4 and P-gp (such as cobicistat, ketoconazole, itraconazole, posaconazole, or&#xD;
             ritonavir).&#xD;
&#xD;
          6. Pregnancy (documentation of use of effective contraception if sexually active or&#xD;
             negative B- Hcg required)&#xD;
&#xD;
          7. Severe renal insufficiency (Creatinine clearance &lt;30 mL/min (defined by&#xD;
             Cockcroft-Gault) in the previous 3 months&#xD;
&#xD;
          8. Documented severe liver disease (eg. acute clinical hepatitis, chronic active&#xD;
             hepatitis or cirrhosis) in the previous 3 months&#xD;
&#xD;
          9. Known thrombocytopenia (platelet count &lt; 50x 109/L) in the previous 3 months&#xD;
&#xD;
         10. Allergy to rivaroxaban&#xD;
&#xD;
         11. Life expectancy &lt;3 months&#xD;
&#xD;
         12. History of condition at increased bleeding risk including, but not limited to:&#xD;
&#xD;
             a. cerebral infarction (hemorrhagic or ischemic), active peptic ulcer disease with&#xD;
             recent bleeding, spontaneous or acquired impairment of hemostasis in the past 4 weeks.&#xD;
             b. Chronic hemorrhagic disorder&#xD;
&#xD;
         13. Primary malignancy diagnosis of basal cell or squamous cell carcinoma of the skin&#xD;
&#xD;
         14. Refused or unable to obtain consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Marc Carrier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chantal Rockwell</last_name>
    <phone>613-737-8899</phone>
    <email>crockwell@ohri.ca</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

